Citations

Clear

904 citation(s) found for "Gordon, S".

Telecare for Patients With Type 1 Diabetes and Inadequate Glycemic Control
Smith, Steven A., Kudva, Yogish C. , Montori, Víctor M. , Guyatt, Gordon

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 28 | Issue: 1 | Pages: 229-230

10.2337/diacare.28.1.229 Get It

Telecare for Patients With Type 1 Diabetes and Inadequate Glycemic Control
Montori, Víctor M. , Helgemoe, Pamela K., Dean, Diana S., Leung, Teresa W., Smith, Steven A., Kudva, Yogish C. , Helgemoe, Pamela, Guyatt, Gordon , Montori, Victor M

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 27 | Issue: 5 | Pages: 1088-1094

10.2337/diacare.27.5.1088 | PMID 15111526 Get It

OBJECTIVE—To determine the efficacy of telecare (modem transmission of glucometer data and clinician feedback) to support intensive insulin therapy in patients with type 1 diabetes and inadequate glycemic control. RESEARCH DESIGN AND METHODS—Thirty-one patients with type 1 diabetes on intensive insulin therapy and with HbA1c >7.8% were randomized to telecare (glucometer transmission with feedback) or control (glucometer transmission without feedback) for 6 months. The primary end point was 6-month HbA1c. To place our findings in context, we pooled HbA1c change from baseline reported in randomized trials of telecare identified in a systematic review of the literature. RESULTS—Compared with the control group, telecare patients had a significantly lower 6-month HbA1c (8.2 vs. 7.8%, P = 0.03, after accounting for HbA1c at baseline) and a nonsignificant fourfold greater chance of achieving 6-month HbA1c ≤7% (29 vs. 7%; risk difference 21.9%, 95% CI −4.7 to 50.5). Nurses spent 50 more min/patient giving feedback on the phone with telecare patients than with control patients. Meta-analysis of seven randomized trials of adult patients with type 1 diabetes found a 0.4% difference (95% CI 0–0.8) in HbA1c mean change from baseline between the telecare and control groups. CONCLUSIONS—Telecare is associated with small effects on glycemic control in patients with type 1 diabetes on intensive insulin therapy but with inadequate glycemic control.
Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997
Grever, Michael R. , Lucas, David , Dewald, Gordon W., Reed, John C. , Kitada, Shinichi, Flinn, Ian W. , Tallman, Martin S. , Appelbaum, Frederick R. , Larson, Richard A. , Paietta, Elisabeth , Jelinek, Diane F., Byrd, John C. , Byrd, John C. , Neuberg, Donna , Gribben, John G. , Larson, Richard A , Flinn, Ian W , Byrd, John C

Mayo Clinic

Journal of Clinical Oncology | February 5, 2007 | Volume: 25 | Issue: 7 | Pages: 799-804

10.1200/jco.2006.08.3089 | PMID 17283363 Get It

Purpose Genomic features including unmutated immunoglobulin variable region heavy chain (IgV H ) genes, del(11q22.3), del(17p13.1), and p53 mutations have been reported to predict the clinical course and overall survival of patients with chronic lymphocytic leukemia (CLL). In addition, ZAP-70 and Bcl-2 family proteins have been explored as predictors of outcome. Patients and Methods We prospectively evaluated the prognostic significance of a comprehensive panel of laboratory factors on both response and progression-free survival (PFS) using samples and data from 235 patients enrolled onto a therapeutic trial. Patients received either fludarabine (FL; n = 113) or fludarabine plus cyclophosphamide (FC; n = 122) as part of a US Intergroup randomized trial for previously untreated CLL patients. Results Complete response (CR) rates were 24.6% for patients receiving FC and 5.3% for patients receiving FL (P = .00004). PFS was statistically significantly longer in patients receiving FC (median, 33.5 months for patients receiving FC and 19.9 months for patients receiving FL; P < .0001). The occurrence of del(17p13.1) (hazard ratio, 3.428; P = .0002) or del(11q22.3) (hazard ratio, 1.904; P = .006) was associated with reduced PFS. CR and overall response rates were not significantly different based on cytogenetics, IgV H mutational status, CD38 expression, or p53 mutational status. Expression of ZAP-70, Bcl-2, Bax, Mcl-1, XIAP, Caspase-3, and Traf-1 was not associated with either clinical response or PFS. Conclusion These results support the use of interphase cytogenetic analysis, but not IgV H , CD38 expression, or ZAP-70 status, to predict outcome of FL-based chemotherapy. Patients with high-risk cytogenetic features should be considered for alternative therapies.
Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997
Flinn, Ian W. , Grever, Michael R. , Dewald, Gordon W., Bennett, John M. , Paietta, Elisabeth , Hussein, Mohamad A., Appelbaum, Frederick R. , Larson, Richard A. , Moore, Dennis F., Tallman, Martin S. , Neuberg, Donna , Larson, Richard A , Flinn, Ian W

Mayo Clinic

Journal of Clinical Oncology | February 5, 2007 | Volume: 25 | Issue: 7 | Pages: 793-798

10.1200/jco.2006.08.0762 | PMID 17283364 Get It

Purpose The combination of fludarabine and cyclophosphamide is an effective regimen for patients with chronic lymphocytic leukemia (CLL). However, it may be accompanied by increased toxicity compared with fludarabine alone. E2997 is a phase III randomized Intergroup trial comparing fludarabine and cyclophosphamide (FC arm) versus fludarabine (F arm) alone in patients receiving their first chemotherapy regimen for CLL. Patients and Methods Symptomatic, previously untreated patients with CLL were randomly assigned to receive either fludarabine 25 mg/m 2 intravenously (IV) days 1 through 5 or cyclophosphamide 600 mg/m 2 IV day 1 and fludarabine 20 mg/m 2 IV days 1 through 5. These cycles were repeated every 28 days for a maximum of six cycles. Results A total of 278 patients were randomly assigned in this Intergroup study. Treatment with fludarabine and cyclophosphamide was associated with a significantly higher complete response (CR) rate (23.4% v 4.6%; P < .001) and a higher overall response (OR) rate (74.3% v 59.5%, P = .013) than treatment with fludarabine as a single agent. Progression-free survival (PFS) was also superior in patients treated with fludarabine and cyclophosphamide than those treated with fludarabine (31.6 v 19.2 months, P < .0001). Fludarabine and cyclophosphamide caused additional hematologic toxicity, including more severe thrombocytopenia (P = .046), but it did not increase the number of severe infections (P = .812). Conclusion Fludarabine and cyclophosphamide produced an increase in OR and CR, and it improved PFS in patients with previously untreated CLL compared with fludarabine alone and was not associated with an increase in infectious toxicity.
Ebstein’s Anomaly
Jost, Christine H. Attenhofer , Connolly, Heidi M. , Dearani, Joseph A. , Edwards, William D. , Danielson, Gordon K.

Mayo Clinic

Circulation | January 16, 2007 | Volume: 115 | Issue: 2 | Pages: 277-285

10.1161/circulationaha.106.619338 | PMID 17228014 Get It

Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia
Hunter, Christine , Dolimbek, Behzod Z., Dolimbek, Gulnoz S., Brashear, Allison , Comella, Cynthia , Gordon, Mark Forrest , Riley, David E., Singer, Carlos , Stacy, Mark, Tarsy, Daniel, Atassi, M. Zouhair, Jankovic, Joseph J. , Adler, Charles H. , Sethi, Kapil D.

Mayo Clinic

Neurology | December 26, 2006 | Volume: 67 | Issue: 12 | Pages: 2233-2235

10.1212/01.wnl.0000249308.66959.43 | PMID 17190952 Get It

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial
Moorman, Anthony V. , Harrison, Christine J. , Buck, Georgina , Richards, Sue, Secker‐Walker, Lorna M., Martineau, Mary, Vance, Gail H. , Cherry, Athena M. , Higgins, Rodney R. , Foroni, Letizia, Paietta, Elisabeth , Tallman, Martin S. , Litzow, Mark R. , Wiernik, Peter H. , Rowe, Jacob M. , Goldstone, Anthony H., Dewald, Gordon W., Fielding, Adele K. , Harrison, Christine J

Mayo Clinic

Blood | December 14, 2006 | Volume: 109 | Issue: 8 | Pages: 3189-3197

10.1182/blood-2006-10-051912 | PMID 17170120 Get It

Abstract Pretreatment cytogenetics is a known predictor of outcome in hematologic malignancies. However, its usefulness in adult acute lymphoblastic leukemia (ALL) is generally limited to the presence of the Philadelphia (Ph) chromosome because of the low incidence of other recurrent abnormalities. We present centrally reviewed cytogenetic data from 1522 adult patients enrolled on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. The incidence and clinical associations for more than 20 specific chromosomal abnormalities are presented. Patients with a Ph chromosome, t(4;11)(q21;q23), t(8;14)(q24.1;q32), complex karyotype (5 or more chromosomal abnormalities), or low hypodiploidy/near triploidy (Ho-Tr) all had inferior rates of event-free and overall survival when compared with other patients. In contrast, patients with high hyperdiploidy or a del(9p) had a significantly improved outcome. Multivariate analysis demonstrated that the prognostic relevance of t(8;14), complex karyotype, and Ho-Tr was independent of sex, age, white cell count, and T-cell status among Ph-negative patients. The observation that Ho-Tr and, for the first time, karyotype complexity confer an increased risk of treatment failure demonstrates that cytogenetic subgroups other than the Ph chromosome can and should be used to risk stratify adults with ALL in future trials.
Physical Mapping of a Translocation Breakpoint in Neurofibromatosis
Fountain, Jane W., BRUCE, M, Seizinger, Bernd R., Menon, Anil G. , Gusella, James F. , Michels, Virginia V., Schmidt, Michael A. , Dewald, Gordon W., Collins, Francis S. , Wallace, Margaret R.

Mayo Clinic

Science | October 5, 2006 | Volume: 244 | Issue: 4908 | Pages: 1085-1087

10.1126/science.2543076 | PMID 2543076 Get It

The gene for von Recklinghausen neurofibromatosis (NF1), one of the most common autosomal-dominant disorders of humans, was recently mapped to chromosome 17 by linkage analysis. The identification of two NF1 patients with balanced translocations that involved chromosome 17q11.2 suggests that the disease can arise by gross rearrangement of the NF1 locus, and that the NF1 gene might be identified by cloning the region around these translocation breakpoints. To further define the region of these translocations, a series of chromosome 17 Not I-linking clones has been mapped to proximal 17q and studied by pulsed-field gel electrophoresis. One clone, 17L1 (D17S133), clearly identifies the breakpoint in an NF1 patient with a t(1;17) translocation. A 2.3-megabase pulsed-field map of this region was constructed and indicates that the NF1 breakpoint is only 10 to 240 kilobases away from 17L1. This finding prepares the way for the cloning of NF1 .
Origin of chi46,XX/46,XY Chimerism in a Human True Hermaphrodite
Dewald, Gordon W., Haymond, Morey W. , Spurbeck, Jack L., Moore, S. Breanndan

Mayo Clinic

Science | October 5, 2006 | Volume: 207 | Issue: 4428 | Pages: 321-323

10.1126/science.7350665 | PMID 7350665 Get It

Using chromosome heteromorphisms and blood cell types as genetic markers, we demonstrated chimerism in a chi46,XX/46,XY true hermaphrodite. The pattern of inheritance of the chromosome heteromorphisms indicates that this individual was probably conceived by the fertilization, by two different spermatozoa, of an ovum and the second meiotic division polar body derived from the ovum and subsequent fusion of the two zygotes. This conclusion is based on the identification of the same maternal chromosomes 13, 16, and 21 in both the 46,XX and 46,XY cells of the patient. In the two cell lines of the chimera, chromosomal markers showed different paternal No. 9 chromosomes and sex chromosomes, as well as the same paternal chromosome 22.
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
Geyer, Susan M. , Call, Timothy G. , Jelinek, Diane F., Tschumper, Renee C. , Bone, Nancy D., Dewald, Gordon W., Lin, Thomas S., Heerema, Nyla A. , Smith, Lisa , Grever, Michael R., Byrd, John C., Byrd, John C. , Kay, Neil E. , Shanafelt, Tait D. , Zent, Clive S. , Byrd, John C

Mayo Clinic

Blood | September 29, 2006 | Volume: 109 | Issue: 2 | Pages: 405-411

10.1182/blood-2006-07-033274 | PMID 17008537 Get It

AbstractBuilding on the prior work of use of pentostatin in chronic lymphocytic leukemia (CLL), we initiated a trial of combined pentostatin (2 mg/m2), cyclophosphamide (600 mg/m2), and rituximab (375 mg/m2) for 65 symptomatic, previously untreated patients. Of 64 evaluable patients, 34 (53%) were high Rai risk, 71% were nonmutated for the immunoglobulin heavy-chain variable region gene, 34% were CD38+, and 34% were ZAP-70+. Thirty patients (52%) had one anomaly detected by fluorescence in situ (FISH) hybridization, and 21 (36%) had complex FISH defects. Thirty-eight patients (58%) had grade 3+ hematologic toxicity but minimal transfusion needs and no major infections. Responses occurred in 58 patients (91%), with 26 (41%) complete responses (CRs), 14 (22%) nodular partial responses (nodular PRs), and 18 (28%) partial responses (PRs). Many patients with a CR also lacked evidence of minimal residual disease by 2-color flow cytometry. Examination of prognostic factors demonstrated poor response in the 3 patients with del(17p). In contrast, we found this regimen was equally effective in young versus older (> 70 years) patients and in del(11q22.3) versus other favorable prognostic factors. Thus, this novel regimen of pentostatin, cyclophosphamide, and rituximab for previously untreated patients with CLL demonstrated significant clinical activity despite poor risk-based prognoses, achievement of minimal residual disease in some, and modest toxicity.